SCHEMBL6324304

SCHEMBL6324304

COc1ccc(-c2noc(N)c2C(=O)NCCCCc2ccccc2)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
TSHR P16473 1/20 0.46
CNR1 P21554 1/20 0.43
FAAH O00519 1/20 0.42
GABRA5 P31644 4/20 0.42
HDAC6 Q9UBN7 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC3 O15379 2/20 0.42
NCOR2 Q9Y618 2/20 0.42
MAPT P10636 2/20 0.42
HDAC4 P56524 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317605 0.97 L3MBTL1 (0.57) L3MBTL1TSHRCNR1FAAHGABRA5
SCHEMBL6324006 0.93 MAPT (0.48) L3MBTL1FAAHMEN1KMT2AMAPT
SCHEMBL6324039 0.88 ALDH1A1 (0.52) TSHRMEN1KMT2AHDAC1MAPT
SCHEMBL6323798 0.88 GAA (0.45) L3MBTL1TSHRGABRA5HDAC6MEN1
SCHEMBL6319295 0.87 GAA (0.44) TSHRGABRA5HDAC6MEN1KMT2A
SCHEMBL6316456 0.87 GAA (0.44) TSHRGABRA5HDAC6MEN1KMT2A
SCHEMBL6323334 0.87 GAA (0.44) TSHRGABRA5HDAC6MEN1KMT2A
SCHEMBL6315289 0.86 RAB9A (0.46) L3MBTL1TSHRGABRA5MEN1KMT2A
SCHEMBL6317731 0.85 SMN1; SMN2 (0.51) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL6316636 0.85 HIF1A (0.50) MEN1KMT2AMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885TSHR 3971/4885CNR1 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.